Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation
H Sohara,
S Amitani,
M Kurose,
and
K Miyahara
Division of Cardiology, Shinkyo Hospital, Kagoshima, Japan.
OBJECTIVES: To determine whether atrial fibrillation (AF) alone affects the fibrinocoagulation system, we examined the relation between fibrinocoagulation activity and duration of AF in patients with paroxysmal AF (PAF). BACKGROUND: Patients with chronic AF are at higher risk for stroke and a hypercoagulative state. It is not clear whether this hypercoagulative state is attributable to AF alone or to the underlying disease. There are no reports on the fibrinocoagulation properties in PAF. METHODS: Fibrinocoagulation variables in 21 patients with PAF were measured during AF and 7 days after recovery of sinus rhythm. There were positive correlations between the duration of AF and beta-thromboglobulin, platelet factor 4, thrombin-antithrombin III complex and fibrinogen. These variables increased significantly 12 h after the occurrence of PAF; thus, patients were classified into two groups according to the duration of PAF: PAF-I group (< 12 h, n = 10), PAF-II group (> or = 12 h, n = 11). Nine age-matched, healthy subjects formed the control group. RESULTS: Levels of beta-thromboglobulin and platelet factor 4 were significantly higher (p < 0.001) by two-way repeated measures analysis of variance (ANOVA), and thrombin-antithrombin III complex and fibrinogen levels tended to be but were not significantly higher (p = 0.06, ANOVA), in the PAF-II group than in the PAF-I group. There were no significant differences between groups in activated partial thromboplastin time, D-dimer or plasmin inhibitor complex. CONCLUSIONS: These results indicate that AF itself enhances platelet aggregation and coagulation, which are influenced by the duration of AF. The acceleration of platelet activity and coagulability occurred 12 h after the occurrence of AF.
This article has been cited by other articles:
|
|
|
|
 
L. D. Sauren, M. la Meir, L. de Roy, L. Pison, F. H. van der Veen, W. H. Mess, H. J. Crijns, and J. G. Maessen
Increased number of cerebral emboli during percutaneous endocardial pulmonary vein isolation versus a thoracoscopic epicardial approach
Eur. J. Cardiothorac. Surg.,
November 1, 2009;
36(5):
833 - 837.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Nagpal, L. Torracca, A. Fumero, P. Denti, M. Cioni, and O. Alfieri
Concurrent prophylactic left atrial appendage exclusion: results from a randomized controlled trial pilot study
Eur. J. Cardiothorac. Surg.,
September 1, 2009;
36(3):
553 - 557.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. G. Akar, W. Jeske, and D. J. Wilber
Acute Onset Human Atrial Fibrillation Is Associated With Local Cardiac Platelet Activation and Endothelial Dysfunction
J. Am. Coll. Cardiol.,
May 6, 2008;
51(18):
1790 - 1793.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Nieuwlaat, T. Dinh, S. B. Olsson, A. J. Camm, A. Capucci, R. G. Tieleman, G. Y.H. Lip, H. J.G.M. Crijns, and on behalf of the Euro Heart Survey Investigators
Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation?
Eur. Heart J.,
April 1, 2008;
29(7):
915 - 922.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Goette, A. Bukowska, U. Lendeckel, M. Erxleben, M. Hammwohner, D. Strugala, J. Pfeiffenberger, F.-W. Rohl, C. Huth, M. P.A. Ebert, et al.
Angiotensin II Receptor Blockade Reduces Tachycardia-Induced Atrial Adhesion Molecule Expression
Circulation,
February 12, 2008;
117(6):
732 - 742.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Duygu, V. Barisik, H. Kurt, U. Turk, E. Ercan, and S. Kose
Prognostic value of plasma soluble CD40 ligand in patients with chronic non-valvular atrial fibrillation
Europace,
February 1, 2008;
10(2):
210 - 214.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Kirchhof, A. Auricchio, J. Bax, H. Crijns, J. Camm, H.-C. Diener, A. Goette, G. Hindricks, S. Hohnloser, L. Kappenberger, et al.
Outcome parameters for trials in atrial fibrillation: executive summary: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA)
Eur. Heart J.,
November 2, 2007;
28(22):
2803 - 2817.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Kirchhof, A. Auricchio, J. Bax, H. Crijns, J. Camm, H.-C. Diener, A. Goette, G. Hindricks, S. Hohnloser, L. Kappenberger, et al.
Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association
Europace,
November 1, 2007;
9(11):
1006 - 1023.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hammwohner, A. Ittenson, J. Dierkes, A. Bukowska, H. U. Klein, U. Lendeckel, and A. Goette
Platelet Expression of CD40/CD40 Ligand and Its Relation to Inflammatory Markers and Adhesion Molecules in Patients with Atrial Fibrillation
Experimental Biology and Medicine,
April 1, 2007;
232(4):
581 - 589.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Writing Committee Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al.
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Europace,
September 1, 2006;
8(9):
651 - 745.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
J. Am. Coll. Cardiol.,
August 15, 2006;
48(4):
e149 - e246.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Circulation,
August 15, 2006;
114(7):
e257 - e354.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Demir, M. Soylu, O. Ozdemir, S. Topaloglu, D. Aras, A. Iasmaz, and I. Korkmaz
Do Different Atrial Flutter Types Carry the Same Thromboembolic Risk?
Angiology,
September 1, 2005;
56(5):
593 - 599.
[Abstract]
[PDF]
|
|
|
|
|
|
|
H. J. Kim and R. Arora
Emerging Role of Direct Thrombin Inhibitors in Nonvalvular Atrial Fibrillation: Potential and Peril
Journal of Cardiovascular Pharmacology and Therapeutics,
January 1, 2005;
10(1):
11 - 21.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F Marin, V Roldan, V E Climent, A Ibanez, A Garcia, P Marco, F Sogorb, and G Y H Lip
Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation
Heart,
October 1, 2004;
90(10):
1162 - 1166.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Inoue, T. Nozawa, K. Okumura, L. Jong-Dae, A. Shimizu, and K. Yano
Prothrombotic Activity Is Increased in Patients With Nonvalvular Atrial Fibrillation and Risk Factors for Embolism
Chest,
September 1, 2004;
126(3):
687 - 692.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. Wyse and B. J. Gersh
Atrial Fibrillation: A Perspective: Thinking Inside and Outside the Box
Circulation,
June 29, 2004;
109(25):
3089 - 3095.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. G. Conway, P. Buggins, E. Hughes, and G. Y. H. Lip
Relationship of interleukin-6 and C-Reactive protein to the prothrombotic state in chronic atrial fibrillation
J. Am. Coll. Cardiol.,
June 2, 2004;
43(11):
2075 - 2082.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S.G. Conway, L. A. Pearce, B. S.P. Chin, R. G. Hart, and G. Y.H. Lip
Prognostic Value of Plasma von Willebrand Factor and Soluble P-Selectin as Indices of Endothelial Damage and Platelet Activation in 994 Patients With Nonvalvular Atrial Fibrillation
Circulation,
July 1, 2003;
107(25):
3141 - 3145.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Cai, Z. Li, A. Goette, F. Mera, C. Honeycutt, K. Feterik, J. N. Wilcox, S. C. Dudley Jr, D. G. Harrison, and J. J. Langberg
Downregulation of Endocardial Nitric Oxide Synthase Expression and Nitric Oxide Production in Atrial Fibrillation: Potential Mechanisms for Atrial Thrombosis and Stroke
Circulation,
November 26, 2002;
106(22):
2854 - 2858.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kamath, A. D. Blann, B. S. P. Chin, F. Lanza, B. Aleil, J. P. Cazenave, and G. Y. H. Lip
A study of platelet activation in atrial fibrillation and the effects of antithrombotic therapy
Eur. Heart J.,
November 2, 2002;
23(22):
1788 - 1795.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S.G. Conway, L. A. Pearce, B. S.P. Chin, R. G. Hart, and G. Y.H. Lip
Plasma von Willebrand Factor and Soluble P-Selectin as Indices of Endothelial Damage and Platelet Activation in 1321 Patients With Nonvalvular Atrial Fibrillation: Relationship to Stroke Risk Factors
Circulation,
October 8, 2002;
106(15):
1962 - 1967.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. A.Y. Chung, F. Belgore, F. L. Li-Saw-Hee, D. S.G. Conway, A. D. Blann, and G. Y.H. Lip
Is the Hypercoagulable State in Atrial Fibrillation Mediated by Vascular Endothelial Growth Factor?
Stroke,
September 1, 2002;
33(9):
2187 - 2191.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Nakagawa, T. Hirai, N. Shinokawa, S. Takashima, T. Nozawa, H. Asanoi, and H. Inoue
Aortic Spontaneous Echocardiographic Contrast and Hemostatic Markers in Patients With Nonrheumatic Atrial Fibrillation
Chest,
February 1, 2002;
121(2):
500 - 505.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kamath, A.D. Blann, and G.Y.H. Lip
Platelets and atrial fibrillation
Eur. Heart J.,
December 2, 2001;
22(24):
2233 - 2242.
[PDF]
|
|
|
|
|
|
|
G.Y.H. Lip and F.L. L. S. Hee
Paroxysmal atrial fibrillation
QJM,
December 1, 2001;
94(12):
665 - 678.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology
Eur. Heart J.,
October 2, 2001;
22(20):
1852 - 1923.
[PDF]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, R. W. Asinger, D. S. Cannom, H. J. Crijns, R. L. Frye, J. L. Halperin, G. N. Kay, W. W. Klein, S. Levy, et al.
ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology
J. Am. Coll. Cardiol.,
October 1, 2001;
38(4):
1266 - 1266.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N.M. Al-Saady and M. Sopher
Prothrombotic markers in atrial fibrillation: what is new?
Eur. Heart J.,
September 2, 2001;
22(18):
1635 - 1639.
[PDF]
|
|
|
|
|
|
|
F.L Li-Saw-Hee, A.D Blann, D Gurney, and G.Y.H Lip
Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function
Eur. Heart J.,
September 2, 2001;
22(18):
1741 - 1747.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. S. Chugh, J. L. Blackshear, W.-K. Shen, S. C. Hammill, and B. J. Gersh
Epidemiology and natural history of atrial fibrillation: clinical implications
J. Am. Coll. Cardiol.,
February 1, 2001;
37(2):
371 - 378.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. L. Li-Saw-Hee, A. D. Blann, and G. Y. H. Lip
A cross-sectional and diurnal study of thrombogenesis among patients with chronic atrial fibrillation
J. Am. Coll. Cardiol.,
June 1, 2000;
35(7):
1926 - 1931.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. M. Feinberg, L. A. Pearce, R. G. Hart, M. Cushman, E. S. Cornell, G. Y.H. Lip, and E. G. Bovill
Markers of Thrombin and Platelet Activity in Patients With Atrial Fibrillation : Correlation With Stroke Among 1531 Participants in the Stroke Prevention in Atrial Fibrillation III Study
Stroke,
December 1, 1999;
30(12):
2547 - 2553.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. G. Hart and J. L. Halperin
Atrial Fibrillation and Thromboembolism: A Decade of Progress in Stroke Prevention
Ann Intern Med,
November 2, 1999;
131(9):
688 - 695.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. I. Silverman and W. J. Manning
Role of Echocardiography in Patients Undergoing Elective Cardioversion of Atrial Fibrillation
Circulation,
August 4, 1998;
98(5):
479 - 486.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M Oppenheimer and J. Lima
Neurology and the heart
J. Neurol. Neurosurg. Psychiatry,
March 1, 1998;
64(3):
289 - 297.
[Full Text]
[PDF]
|
|
|
|
